ADMA - ADMA Biologics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.0800
+0.0200 (+0.49%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.0600
Open4.1600
Bid3.6300 x 4000
Ask4.1700 x 3000
Day's Range3.9700 - 4.2000
52 Week Range2.0800 - 6.9600
Volume628,617
Avg. Volume783,837
Market Cap242.017M
Beta (3Y Monthly)2.63
PE Ratio (TTM)N/A
EPS (TTM)-1.2430
Earnings DateMar 7, 2019 - Mar 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.19
Trade prices are not sourced from all markets
  • GlobeNewswire

    ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

    RAMSEY, N.J. and BOCA RATON, Fla., Aug. 22, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • Breakeven On The Horizon For ADMA Biologics, Inc. (NASDAQ:ADMA)
    Simply Wall St.

    Breakeven On The Horizon For ADMA Biologics, Inc. (NASDAQ:ADMA)

    ADMA Biologics, Inc.'s (NASDAQ:ADMA): ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company...

  • GlobeNewswire

    ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results

    RAMSEY, N.J. and BOCA RATON, Fla., Aug. 08, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire

    ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces the United States Food and Drug Administration (“FDA”) has notified ADMA the licenses for BIVIGAM® and Nabi-HB® have been revoked from Biotest Pharmaceuticals Corporation, (“BPC”) U.S. License No. 1792 and transferred and issued to ADMA’s U.S. License No. 2019.

  • Did ADMA Biologics, Inc. (NASDAQ:ADMA) Insiders Buy Up More Shares?
    Simply Wall St.

    Did ADMA Biologics, Inc. (NASDAQ:ADMA) Insiders Buy Up More Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • How Many ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Did Insiders Buy, In The Last Year?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • GuruFocus.com

    ADMA Biologics: Selloff Creates Buying Opportunity

    The fundamental growth story is intact

  • PR Newswire

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ADMA Biologics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , June 6, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...

  • GuruFocus.com

    ADMA Biologics Is De-Risked and Ready to Rise

    After years of struggle, ADMA Biologics (ADMA) appears at last to be poised for bigger things. The Food and Drug Administration's recent approval of two of its intravenous immune globulin (IVIG) drug products, Asceniv and Bivigam, has put this stock back on the radar. Combined with a timely capital raise, ADMA's two new products should set it up for an impressive breakout in the second half of 2019.

  • GlobeNewswire

    ADMA Biologics to Present at Upcoming Investor Conferences

    Jefferies 2019 Healthcare Conference Raymond James Life Sciences and MedTech Conference RAMSEY, N.J. and BOCA RATON, Fla., May 29, 2019 -- ADMA Biologics, Inc. (NASDAQ:.

  • TheStreet.com

    These 3 Biotech Stocks Are Attracting Insider Buying

    Volatility continues to pick up as trade tensions between the U.S. and China continue to escalate with no current end in sight. Add in EU elections and the coming departure of the prime minister in the U.

  • GlobeNewswire

    ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced today the closing of its previously announced underwritten public offering of 12,937,500 shares of its common stock at a public offering price of $4.00 per share, including 1,687,500 shares of common stock issued upon the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from the offering are $51.75 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

  • GuruFocus.com

    Adma Biologics Inc (ADMA) President and CEO Adam S Grossman Bought $120,000 of Shares

    President and CEO of Adma Biologics Inc (NASDAQ:ADMA) Adam S Grossman bought 30,000 shares of ADMA on 05/17/2019 at an average price of $4 a share.

  • GlobeNewswire

    NeuBase Therapeutics Designates Industry Leaders to Board of Directors 

    NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced that it has designated four experienced executives from the biotechnology industry for its board of directors (the “Board”), including Dov A. Goldstein, M.D., M.B.A., Diego Miralles, M.D., Franklyn Prendergast, M.D., Ph.D., and Eric Richman, M.B.A, to become effective upon the closing of the Company’s merger with Ohr Pharmaceutical, Inc. (OHRP) (“Ohr”). The four designees, together with Dietrich A. Stephan, Ph.D., chairman and chief executive officer of the company, will comprise the entire board of directors for the combined company.

  • GlobeNewswire

    ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced today that it has commenced a $45 million underwritten public offering of its common stock. The Company intends to grant the underwriter of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. Jefferies LLC is acting as sole book-running manager of the proposed offering.

  • GlobeNewswire

    FDA Approves Prior Approval Supplement for BIVIGAM®

    RAMSEY, N.J. and BOCA RATON, Fla., May 10, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • Associated Press

    Adma Biologics: 1Q Earnings Snapshot

    The Ramsey, New Jersey-based company said it had a loss of 28 cents per share. Losses, adjusted for non-recurring gains, came to 31 cents per share. The results topped Wall Street expectations. The average ...

  • GlobeNewswire

    ADMA Biologics Reports First Quarter 2019 Financial Results

    RAMSEY, N.J. and BOCA RATON, Fla., May 08, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire

    ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection.  The patent claims encompass methods of preparing immune globulin via harvesting plasma from S. pneumonia vaccinated, healthy adult human donors and pooling the harvested plasma as the source for manufacturing a hyperimmune anti-pneumococcal immune globulin containing elevated opsonic antibodies to a plurality of S. pneumonia serotypes. The issued claims also encompass hyperimmune anti-pneumococcal immune globulin so prepared, methods of treating S. pneumonia infection and methods of providing immunotherapy using the hyperimmune anti-pneumococcal immune globulin.

  • ADMA Biologics: Wall Street Projects Robust Revenue Growth
    Market Realist

    ADMA Biologics: Wall Street Projects Robust Revenue Growth

    Why ADMA Biologics Stock Soared Yesterday(Continued from Prior Part)Revenue growth estimates ADMA Biologics (ADMA) has two commercialized assets in its portfolio, Nabi-HB and BIVIGAM, which it added through the acquisition of assets from Biotest

  • Why ADMA Biologics Stock Soared Yesterday
    Market Realist

    Why ADMA Biologics Stock Soared Yesterday

    Why ADMA Biologics Stock Soared YesterdayShare price movements Yesterday, ADMA Biologics (ADMA) closed at $5.06, which is about 24.32% higher than its previous closing price, 143.27% higher than its 52-week low of $2.08, and 27.30% lower than its

  • Benzinga

    The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...

  • GlobeNewswire

    ADMA Receives Department of Health and Human Services U.S. License

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that the U.S. Food and Drug Administration (“FDA”) has issued a Department of Health and Human Services U.S. license No. 2019 to the Company in connection with the approval of ASCENIV™ Immune Globulin Intravenous, Human – slra 10% Liquid.

  • Benzinga

    ADMA Biologics Rips Higher On FDA Nod For Immunodeficiency Therapy

    ADMA announced Monday after the market close that the FDA approved its Asceniv, a novel, patented, intravenous immunoglobulin product for the treatment of primary humoral immunodeficiency disease, or PIDD, in adults and adolescents ages 12-17. PIDD is a collective name for more than 300 diseases that occur due to defects in the body's immune system, invariably manifesting as acute or recurrent infections. Asceniv is manufactured using ADMA's unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends the source plasma and plasma from donors testing using its proprietary microneutralization assay.